Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.24 -3.1%	$0.27	$0.20 ▼ $1.48	$64.22M	2.24	1.71 million shs	564,916 shs
ARMP Armata Pharmaceuticals	$1.87 -7.0%	$1.58	$0.90 ▼ $3.42	$67.66M	0.87	69,813 shs	17,405 shs
EPIX ESSA Pharma	$1.67 -1.8%	$1.70	$1.40 ▼ $7.88	$74.13M	1.58	340,367 shs	39,103 shs
LTUS Lotus Pharmaceuticals	$0.01 -12.7%	$0.01	$0.00 ▼ $0.01	$18.25M	-2.48	60,362 shs	627 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	0.00%	-14.38%	-8.46%	-46.19%	-76.70%
ARMP Armata Pharmaceuticals	0.00%	-5.56%	+33.57%	-4.10%	-48.91%
EPIX ESSA Pharma	0.00%	-2.34%	-2.34%	+3.09%	-67.88%
LTUS Lotus Pharmaceuticals	0.00%	+38.00%	+30.19%	-12.66%	+130.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAP Adaptimmune Therapeutics	3.1371 of 5 stars	4.2	5.0	0.0	0.0	2.2	0.8	0.0
ARMP Armata Pharmaceuticals	2.2559 of 5 stars	3.5	3.0	0.0	0.0	2.5	1.7	0.0
EPIX ESSA Pharma	1.9946 of 5 stars	2.0	3.0	0.0	0.0	2.7	2.5	1.3
LTUS Lotus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	2.43	Hold	$1.52	526.63% Upside
ARMP Armata Pharmaceuticals	3.00	Buy	$9.00	381.28% Upside
EPIX ESSA Pharma	2.00	Hold	$2.00	19.76% Upside
LTUS Lotus Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest LTUS, EPIX, ARMP, and ADAP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2025	ARMP Armata Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $9.00
5/14/2025	ADAP Adaptimmune Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$1.50 ➝ $1.00
5/14/2025	ADAP Adaptimmune Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$1.00 ➝ $0.46
4/11/2025	ADAP Adaptimmune Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/1/2025	ADAP Adaptimmune Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.50 ➝ $3.00
3/26/2025	ADAP Adaptimmune Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.00 ➝ $1.75
3/21/2025	ADAP Adaptimmune Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$2.00 ➝ $1.50
3/21/2025	ADAP Adaptimmune Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$3.15 ➝ $1.40

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$179.64M	0.36	N/A	N/A	$0.17 per share	1.43
ARMP Armata Pharmaceuticals	$4.53M	14.94	N/A	N/A	($0.89) per share	-2.10
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	$2.68 per share	N/A
LTUS Lotus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$113.87M	-$0.27	N/A	N/A	N/A	-25.43%	-74.15%	-15.09%	8/11/2025 (Estimated)
ARMP Armata Pharmaceuticals	-$69.04M	-$1.64	N/A	N/A	N/A	N/A	N/A	-60.91%	8/12/2025 (Estimated)
EPIX ESSA Pharma	-$28.54M	-$0.63	N/A	N/A	N/A	N/A	-24.61%	-23.87%	8/4/2025 (Estimated)
LTUS Lotus Pharmaceuticals	-$20K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest LTUS, EPIX, ARMP, and ADAP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ADAP Adaptimmune Therapeutics	-$0.18	-$0.18	N/A	-$0.18	$6.55 million	$7.29 million
5/8/2025	Q2 2025	EPIX ESSA Pharma	-$0.19	-$0.14	+$0.05	-$0.14	N/A	N/A
3/24/2025	Q4 2024	ADAP Adaptimmune Therapeutics	-$0.17	-$0.26	-$0.09	-$0.29	$16.56 million	$3.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
ARMP Armata Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	N/A
LTUS Lotus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	0.62	3.85	3.82
ARMP Armata Pharmaceuticals	N/A	0.19	0.19
EPIX ESSA Pharma	N/A	33.12	33.12
LTUS Lotus Pharmaceuticals	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
ARMP Armata Pharmaceuticals	3.57%
EPIX ESSA Pharma	75.12%
LTUS Lotus Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.74%
ARMP Armata Pharmaceuticals	85.50%
EPIX ESSA Pharma	15.50%
LTUS Lotus Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	490	265.05 million	224.05 million	Optionable
ARMP Armata Pharmaceuticals	70	36.18 million	5.25 million	Not Optionable
EPIX ESSA Pharma	50	44.39 million	37.51 million	Optionable
LTUS Lotus Pharmaceuticals	230	2.64 billion	N/A	Not Optionable

LTUS, EPIX, ARMP, and ADAP Headlines

Recent News About These Companies

Lotus Therapeutics Appoints Leslie Felix as Chief Growth Officer

June 4, 2025 | finance.yahoo.com

Speranza Therapeutics Launches New Division to Help Pharma Manufacturers Adapt to Market Shifts

April 23, 2025 | finance.yahoo.com

Lotus Pharmaceutical becomes strategic partner for…

February 5, 2025 | pharmiweb.com

Taiwan’s pharma firm Lotus acquires edema medicine rights in Vietnam from Sanofi

January 9, 2025 | theinvestor.vn

lotus exchange

December 28, 2024 | everythingexperiential.businessworld.in

Boryung, Lotus Pharma signs CDMO deal on anticancer injection

December 12, 2024 | kedglobal.com

Lotus Pharmaceuticals Inc Price / Book

November 20, 2024 | investing.com

Lotus Bakeries: When Growth Potential Meets Pricey Expectations

November 13, 2024 | seekingalpha.com

USA Knotless Surgical Sutures Market Expected to Reach USD 258.7 Million by 2033 at a 3.6% of CAGR

November 1, 2024 | fmiblog.com

20 Shows Like ‘Black Mirror’ That’ll Definitely Mess with Your Head

November 1, 2024 | yahoo.com

Lotus Bakeries: A Sweet Business With Exponential Growth

October 27, 2024 | seekingalpha.com

A Forbidden Lotus Elise Rival Is for Sale in the U.S. Right Now

October 24, 2024 | msn.com

Natasha Rothwell Opens Up About 'The White Lotus' Season 3, 'How to Die Alone' & More

October 23, 2024 | msn.com

Lotus Resources Plans Equity Raise for Uranium Project

October 22, 2024 | markets.businessinsider.com

Lotus of Love Cancer Inc

October 20, 2024 | msn.com

This 90s-Era GM-Lotus Mashup Was The Ultimate Sleeper Sedan

October 19, 2024 | topspeed.com

Why Romantics Love the Lotus Sex Position, According to a Sexologist

October 9, 2024 | popsugar.com

Topic: @lotus

October 9, 2024 | arstechnica.com

2025 Lotus Emira Gets 400-HP Turbo SE Version

October 9, 2024 | autoevolution.com

See CEO plans as Lotus Bank opens new branch, makes promises

October 8, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LTUS, EPIX, ARMP, and ADAP Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

$0.24 -0.01 (-3.08%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$0.25 +0.01 (+3.18%)

As of 06/13/2025 07:40 PM Eastern

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Armata Pharmaceuticals NYSEAMERICAN:ARMP

$1.87 -0.14 (-6.97%)

Closing price 06/13/2025 04:10 PM Eastern

Extended Trading

$1.92 +0.05 (+2.67%)

As of 06/13/2025 08:00 PM Eastern

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.

ESSA Pharma NASDAQ:EPIX

$1.67 -0.03 (-1.76%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.67 0.00 (0.00%)

As of 06/13/2025 04:08 PM Eastern

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Lotus Pharmaceuticals OTCMKTS:LTUS

$0.0069 0.00 (-12.66%)

As of 06/13/2025 11:39 AM Eastern

Lotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time